NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $7.85 +0.30 (+3.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.52▼$7.8750-Day Range$6.00▼$7.6352-Week Range$4.03▼$7.95Volume2.36 million shsAverage Volume3.41 million shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioCryst Pharmaceuticals alerts: Email Address BioCryst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.8% Upside$14.67 Price TargetShort InterestBearish10.57% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.74Based on 5 Articles This WeekInsider TradingAcquiring Shares$596,338 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.65) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector189th out of 936 stocksBiological Products, Except Diagnostic Industry24th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.57% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 21.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 2.6 News and Social Media Coverage News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioCryst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have bought 622.96% more of their company's stock than they have sold. Specifically, they have bought $596,338.00 in company stock and sold $82,486.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -7.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -7.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More BCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Stock News HeadlinesJuly 9, 2024 | insidertrades.com3 Insider-Buy Stocks to Add to Your Watchlist Now (BCRX)July 22, 2024 | globenewswire.comBioCryst to Report Second Quarter 2024 Financial Results on August 5July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 21, 2024 | seekingalpha.comBetting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future ProspectsJuly 9, 2024 | globenewswire.comORLADEYO® (berotralstat) Approved in PeruJuly 2, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2024 | globenewswire.comBioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 29, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near FutureMay 25, 2024 | benzinga.comBioCryst Pharma Stock (NASDAQ:BCRX), Quotes and News SummaryMay 15, 2024 | finance.yahoo.comInsider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comDirector Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...May 15, 2024 | seekingalpha.comBioCryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare moversMay 14, 2024 | globenewswire.comBioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyMay 13, 2024 | markets.businessinsider.comBiocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema AttacksSee More Headlines Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees536Year Founded1986Price Target and Rating Average Stock Price Target$14.67 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+86.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-58.69% Pretax Margin-58.69% Return on EquityN/A Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.48 Sales & Book Value Annual Sales$331.41 million Price / Sales4.89 Cash FlowN/A Price / Cash FlowN/A Book Value($2.22) per share Price / Book-3.54Miscellaneous Outstanding Shares206,380,000Free Float196,471,000Market Cap$1.62 billion OptionableOptionable Beta1.88 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jon P. Stonehouse (Age 63)CEO, President & Executive Director Comp: $1.23MMr. Anthony J. Doyle (Age 44)Senior VP, CFO & Treasurer Comp: $845.93kMs. Alane P. Barnes (Age 58)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $794.75kMs. Jinky Ang RosselliChief Data & Insights OfficerMr. Philip GeorgeChief Strategy OfficerMr. Clayton FletcherChief Business Development OfficerMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKTaysha Gene TherapiesNASDAQ:TSHAAdaptimmune TherapeuticsNASDAQ:ADAPVaxartNASDAQ:VXRTTCR2 TherapeuticsNASDAQ:TCRRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 86,249 shares on 7/26/2024Ownership: 0.376%Assenagon Asset Management S.A.Sold 321,978 shares on 7/18/2024Ownership: 0.031%Diversified Trust CoBought 3,774 shares on 7/16/2024Ownership: 0.012%CWM LLCBought 3,772 shares on 7/10/2024Ownership: 0.003%Amy E MckeeSold 8,600 sharesTotal: $54,352.00 ($6.32/share)View All Insider TransactionsView All Institutional Transactions BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of 2024. Since then, BCRX stock has increased by 31.1% and is now trading at $7.85. View the best growth stocks for 2024 here. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Monday, May, 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The business's revenue was up 34.9% on a year-over-year basis. What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.38%), Assenagon Asset Management S.A. (0.03%), Diversified Trust Co (0.01%) and CWM LLC. Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones, Vincent Milano and George B Abercrombie. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX) and La Jolla Pharmaceutical (LJPC). This page (NASDAQ:BCRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
